Welcome to our dedicated page for Pavmed news (Ticker: PAVMZ), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (PAVMZ) is a commercial-stage medical technology leader advancing innovative diagnostics, devices, and digital health solutions. This page serves as the definitive source for official company announcements, including product milestones, clinical validations, and strategic partnerships.
Investors and healthcare professionals will find timely updates on PAVmed’s cancer prevention technologies like the EsoGuard® Esophageal DNA Test, developments from subsidiaries Lucid Diagnostics and Veris Health, and regulatory progress across its diversified pipeline. Content spans earnings reports, FDA clearances, research collaborations, and commercialization updates.
All materials are sourced directly from company filings and press releases to ensure accuracy. Bookmark this page to monitor PAVmed’s progress in transforming early disease detection through noninvasive testing and connected health platforms.
FAQ
What is the current stock price of Pavmed (PAVMZ)?
